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Candida guilliermondii AS THE AETIOLOGY OF CANDIDOSIS
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SUMMARY
Candida guilliermondii is one of the components of human microbiota. This yeast has been infrequently associated with
human infections, which may be related to its low pathogenicity. The aim of this study was to provide clinical and epidemiological
data for patients infected with C. guilliermondii at Santa Casa Complexo Hospitalar, Brazil. From October 1997 to October 2003,
C. guilliermondii was isolated from clinical samples from 11 patients. Three patients were excluded because the isolation of the
yeast represented colonisation. Specimens from the eight patients included in the study corresponded to blood (n = 5), ascitis fluid
(n = 2), and oesophagus biopsy (n = 1). Three patients (37.5%) had major immunosuppressed conditions, including solid organ
transplantation, AIDS, and leukaemia. Previous use of antibiotics occurred in 87.5%. Main invasive medical procedures were
central venous catheter (50.0%), abdominal surgery (25.0%), and peritoneal dialysis (50.0%). No susceptibility data was obtained.
Although risk factors for candidaemia were similar amongst patients infected by with C. guilliermondii or other Candida species,
mortality associated with C. guilliermondii was significantly lower.
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INTRODUCTION
The incidence of invasive infections caused by Candida spp. has
notably increased within the past two decades37. In addition, an
increment has been observed in the proportion of infections caused by
species other than Candida albicans, mainly Candida glabrata. The
emergence of non-Candida albicans species is a major concern, since
some of these species may be highly resistant to antifungals, particularly
C. glabrata, C. krusei, C. lusitaniae, and C. guilliermondii. Contrasting
to what occurs in North America and Europe, C. parapsilosis, and C.
tropicalis are - at least at the moment - responsible for the vast majority
of non-Candida albicans infections in Brazil1,12,35,36.
Candida guilliermondii is a component of human microbiota, and
is uncommonly isolated from patients as a pathogen. Owing to their
lower frequency, infections caused by C. guilliermondii are relatively
less studied, in comparison to infections caused by other Candida
species. The aim of this study was to provide clinical and
epidemiological data for patients who had the diagnosis of C.
guilliermondii infection in our medical centre during a 6-year period.
PATIENTS AND METHODS
Santa Casa Complexo Hospitalar is a 1,200-bed Brazilian teaching
hospital that provides tertiary care. The records of the Mycology
Laboratory were reviewed from October 1997 to October 2003,
attempting to identify positive cultures for C. guilliermondii. Clinical
records of these patients were checked.
Samples processing was performed according to standard
mycological techniques. After examination for chlamydospore
production positive strains at germ tubes test were considered to be
Candida albicans. No additional test was performed for the
differentiation of C. albicans and C. dubliniensis. Negative strains at
germ tubes tests were identified at species level using kit ID 32C
(BioMérieux, France). Candidaemia was diagnosed when a peripheral
positive blood culture was temporally related to signs and symptoms.
Histopathologic or cytopathologic examination showing C.
guilliermondii from specimens of needle aspiration or biopsy, excluding
mucous membranes, were considered evidence of invasive infection
as well as a positive culture result on a sample obtained by sterile
procedure from normally sterile site2. Patients considered only
colonised by C. guilliermondii were not included in this study.
RESULTS
From October 1997 to October 2003 C. guilliermondii was isolated
from clinical samples obtained from 11 patients. However, three patients
were excluded from the study because the isolation of the yeast
represented colonisation. The first of these excluded patients had AIDS
and C. guilliermondii isolated from the pericardial fluid, in the absence
of any inflammatory process in the pericardium. The next two patients
124
PASQUALOTTO, A.C.; ANTUNES, A.G.V. & SEVERO, L.C. - Candida guilliermondii as the aetiology of candidosis. Rev. Inst. Med. trop. S. Paulo, 48(3):123-127, 2006.
were liver transplant recipients: one had a single positive urine culture,
in the presence of a urinary catheter, and the other had a positive culture
from a colon biopsy in which no fungal invasion was observed at
histopathology. These three patients discharged with no antifungal
treatment. Thus, eight cases were actually included in the study.
Specimens were obtained from blood (n = 5), ascitis fluid (n = 2),
and oesophagus biopsy (n = 1). Most patients were male (62.8%) and
median age was 29.8 years-old (range, 19 days to 73 years-old). Three
patients (37.5%) had a major immunosuppressed condition, including
solid organ transplantation (n = 1), AIDS (n = 1), and leukaemia (n =
1). Previous use of antibiotics occurred in 87.5% of cases (n = 7).
Invasive medical procedures included central venous catheter (50.0%),
abdominal surgery (25.0%), peritoneal dialysis (50.0%), mechanical
ventilation (25.0%), and parenteral nutrition (12.5%). There was no
report of previous polyene use for any of these patients. These eight
patients are presented below. Table 1 summarizes relevant aspects for
these cases. All patients were treated with antifungals, but one. Overall
mortality was 12.8%.
During the period of study, a total of 190 cases of candidaemia
were documented in our medical centre. C. guilliermondii accounted
for 2.6% of these cases. While the overall mortality for patients with
candidaemia was 48.9% (60.0% for patients infected by C. albicans),
none of the five patients with candidaemia caused by C. guilliermondii
died. Apart from that, no difference was observed amongst patients
with candidaemia caused by C. guilliermondii or other Candida species
regarding demographic features, underlying diseases, and frequency
of invasive medical procedures, antimicrobials use, and other
predisposing conditions to candidaemia. In addition, during the period
of study there were 864 positive cultures for Candida obtained from
oesophagus samples, and 72 positive cultures from dialysis fluid. Thus,
C. guilliermondii was the aetiology of 0.1% and 2.8% of oesophagitis
and dialysis-associated peritonitis caused by Candida species,
respectively.
PATIENTS
Patient 1. A full-term female neonate was submitted to
gastroschisis correction. The postoperative course was complicated
with haemodynamic instability, and the patient was treated with
mechanical ventilation and parenteral nutrition. Therapy also included
multiple empiric antibiotic courses for sepsis, including ampicillin,
gentamicin, vancomycin, cefotaxime, amikacin, and metronidazole.
Twenty days after her birth, C. guilliermondii grew in blood culture.
She completed 25 days of amphotericin B and was discharged from
the hospital.
Patient 2. A 45 year-old man was admitted to the hospital for
secondary pulmonary hypertension attributable to recurrent lung
embolism. Bacteraemia due to K. pneumoniae occurred after pulmonary
arteriography and the patient received a 14-day course of cefuroxime
for this catheter-related infection. Fever relapsed and C. guilliermondii
was isolated from blood culture. Evolution was favourable with 14
days of amphotericin B.
Patient 3. A 6-year-old boy with acute lymphocytic leukaemia
developed fever after chemotherapy. The patient was not neutropenic
and maintained fever despite treatment with amoxicillin-clavulanate.
Blood culture yielded Stenotrophomonas maltophilia and C.
guilliermondii. A port-a-cath infected with S. maltophilia was removed.
The patient was discharged after 13 days of intravenous trimethoprim-
sulfamethoxazole and amphotericin B.
Patient 4. A 73-year-old woman developed lung embolism and
acute cor pulmonale after elective electric cardioversion for intermittent
atrial flutter. She received 14 day of cefuroxime for nosocomial
pneumonia. Her blood was taken out for culture due to leukocytosis,
hypothermia and hypotension, and one out of three samples yielded C.
guilliermondii. The patient became asymptomatic and received no
antifungal therapy.
Patient 5. A 45-year-old immunocompetent man was admitted for
elective cholecystectomy. Cellulitis occurred at peripheral venous site
associated with fever, chills, and hypotension. Three blood cultures
were positive for K. pneumoniae and two were positive for C.
guilliermondii. The peripheral catheter was removed but not sent to
culture. The patient was treated with ampicillin-sulbactam and
fluconazole for seven days, and he was discharged 10 days after the
positive blood cultures for Candida were taken.
Patient 6. A 1-year-old boy with chronic renal failure was in
treatment with continuous ambulatory peritoneal dialysis (CAPD). He
was admitted to the hospital due to fever, abdominal pain, and vomit.
Table 1
Characteristics of the eight patients with infection caused by Candida guilliermondii
Case Sex, Age Underlying conditions Origin of specimen Antifungal treatment, duration
1 F, 19d Abdominal surgery (gastroschisis) Blood AmB 1.1 mg/kg/d, 25 days
2 M, 45y Secondary pulmonary hypertension Blood AmB 1.0 mg/kg/d, 14 days
3 M, 6y Acute lymphocytic leukaemia Blood AmB 0.9 mg/kg/d, 13 days
4 F, 73y Supraventricular arrhythmia Blood No specific treatment
5 M, 45y Cholecystectomy Blood Flu 6.7 mg/kg/d, 7 days
6 M, 1y Peritoneal dialysis Ascitis fluid Flu 4.2 mg/kg/d, 10 days
7 F, 21y Immunosuppressive therapy Ascitis fluid AmB 0.5 mg/kg/d, 6 days, then
Peritoneal dialysis Flu 4 mg/kg/d, 10 days
8 M, 38y AIDS Oesophageal biopsy Flu 4.3 mg/kg/d, 14 days
M = Male; F = Female; AmB = Amphotericin B desoxycholate; Flu = Fluconazole.
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Dialysis fluid was muddy, and C. guilliermondii grew in a sample taken
from CAPD bag. The Tenckhoff catheter was removed and then
reinserted after 10 days of fluconazole. Culture of the previous catheter
yielded Candida spp., and the patient was discharged in good health.
Patient 7. A 21-year-old woman on CAPD was admitted due to
fever, vomits, and abdominal pain. She had been submitted to renal
transplantation five years before. Graft loss occurred due to rejection
and the patient was on prednisone (5 mg daily) and cyclosporine (50
mg daily). At admission, cephalothin and amikacin were empirically
started, and culture taken from CAPD bag revealed pure growth of C.
guilliermondii. After six days of amphotericin B, the catheter was
replaced, and antimicrobial therapy subsequently changed to
fluconazole and cephalothin. Culture of catheter yielded Candida spp..
The patient was discharged after treatment with cefepime for
nosocomial pneumonia.
Patient 8. A 38-year-old male patient with AIDS (CD4 count 46
cells/mm3), idiopathic dilated myocardiopathy, and severe systolic
dysfunction was admitted for pneumonia. He was treated with
ciprofloxacin. Fluconazole was prescribed to treat dysphagia associated
with oral candidosis, and it was further suspended due to hepatotoxicity.
Upper gastrointestinal endoscopy showed oesophageal candidosis with
C. guilliermondii in culture. The patient died due to cardiac failure.
DISCUSSION
Candida guilliermondii seems to be one of the least virulent
amongst Candida species3,7,18,22. In a study using an immunocompetent
mouse model3, eight Candida species could be divided into three
virulence groups of decreasing pathogenicity: (1) C. albicans and C.
tropicalis; (2) C. glabrata, C. lusitaniae and C. kefyr; and (3) C.
parapsilosis, C. krusei and C. guilliermondii. This hierarchic
classification was based on mortality, number of kidneys infected,
clearance of - or established infection in kidneys, CFU counts in tissue,
capacity to involve eyes, and histopathological findings in kidneys. C.
guilliermondii was the species with the lowest pathogenic potential in
this study. In another study21, no mortality was observed in animals
persistently infected with C. guilliermondii. This was associated with
the organism’s failure to cause diffuse involvement of the renal
parenchyma, to produce pseudomycelia, or to invade the renal tubular
lumen. Differently from mice infected with C. parapsilosis,
corticosteroids neither induced progressive infection nor delayed tissue
clearance in C. guilliermondii infections21.
In concordance with its low pathogenicity, C. guilliermondii is
an uncommon aetiology of invasive candidosis, accounting for 0-3%
of candidaemias in Latin America and Brazil1,10-12,19,20,35,36,42. Few
Brazilian studies have documented higher percentages such as 9% to
14%13,29,32,33. These results should be seen with caution. Five cases of
candidaemia were presented here (patients 1-5) and most of these
patients had a favourable response to treatment with amphotericin B
desochycolate. One of these patients had a good clinical evolution
despite the absence of antifungal therapy (case 4). As this
immunocompetent patient had leukocytosis, hypothermia and
hypotension at the time the positive blood culture for Candida was
taken, we considered him as truly infected, not colonised. Transitory
candidaemia may have occurred.
At the moment, no specific risk factor has been described for C.
guilliermondii infections. Furthermore, we found no difference in risk
factors for candidaemia amongst these five patients with candidaemia
caused by C. guilliermondii and 185 patients with candidaemia caused
by other species seen in the same period in our medical centre. Of
importance, the limited number of patients included in this study does
not permit any small differences between these groups to be revealed.
A nosocomial outbreak of C. guilliermondii fungaemia was recently
reported involving five patients admitted to a general surgery unit of a
tertiary care hospital over a 2-week period28. All clinical isolates of C.
guilliermondii were identical when typed by random amplified
polymorphic DNA (RAPD). The evidence for clonality associated with
the fact that at least three of five cases were associated with central
venous catheters led to the conclusion that cross-contamination between
patients and staff probably occurred. This may have important
consequences in terms of infection control policies. A pseudo-outbreak
of C. guilliermondii fungaemia due to contamination of heparin vials
in a neonatal intensive care unit was also reported49.
Two cases of C. guilliermondii peritonitis were presented here,
associated with an infected peritoneal dialysis catheter (patients 6 and
7). Both patients had a good clinical response after antifungal therapy
and catheter removal. Fungal peritonitis occurs in 2-10% of peritoneal
dialysis patients with clinical presentation similar to bacterial infection
(which is more frequent)6. C. guilliermondii peritonitis is a very
uncommon disease5. In a recent review of 46 cases of fungal peritonitis
on peritoneal dialysis patients, only four cases of peritonitis due to C.
guilliermondii were reported6. Another case was reported in a series of
15 patients with fungal peritonitis in patients on CAPD. That particular
strain was resistant to itraconazole25. Other case was reported in India
amongst 28 episodes of fungal peritonitis40.
Candidosis is the most common cause of oropharyngeal disease in
HIV-infected patients and it is usually caused by C. albicans. C.
guilliermondii oesophagitis is not common31,44,47 and it was not found in
a multicentre Brazilian study of 130 patients with AIDS43. Patient 11
reported in our study had the typical clinical presentation of Candida
oesophagitis. These manifestations are common to all Candida species,
and there is no particular finding which could suggest C. guilliermondii
as the aetiologic agent. Oral infections have been reported in diabetic
patients16, and in patients with denture stomatitis8,14,16,17. In one report,
an immunocompentent patient presented with a dento-alveolar abscess
in a polymicrobial infection in which Candida guilliermondii was a co-
pathogen together with two other oral bacteria30. Oral colonisation has
also been described in immunocompentent individuals41,48, patients with
cancer4,45, as well as in those treated with oral inhaled corticosteroids23.
Assuming that C. guilliermondii infections are uncommon and
associated with a low virulence, where do their importance reside?
The answer is antifungal resistance. Together with C. tropicalis and C.
lusitaniae, C. guilliermondii is one of the main Candida species where
polyene resistance has occurred15,24,39. Additionally, isolates of C.
guilliermondii frequently demonstrate higher MICs to other antifungal
drugs, including echinocandins34 and azoles9,38,46. This may be associated
with therapeutic failures and sometimes deaths. Although susceptibility
tests were not performed in the current study, no clinical failure occurred
in patients treated with amphotericin B.
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In conclusion, this study provided clinical data for eight patients
infected with C. guilliermondii. Their characteristics were similar to
what is expected for Candida infections, a frequent association with
antibiotics and catheters. For some patients, the recovery of C.
guilliermondii from clinical specimens represented colonisation.
Aseptic technique should be rigorously performed during the process
of sampling to avoid mistakes in the interpretation of a positive culture.
Mortality associated with C. guilliermondii was very low in comparison
with mortality observed for other Candida species. No clinical failure
occurred in patients treated with amphotericin B desochycolate. Based
on previous reports revealing resistance to several antifungal drugs -
including polyenes, echinocandins, and azoles - routine susceptibility
tests have been suggested for C. guilliermondii infections.
RESUMO
Candida guilliermondii como agente de candidose
Candida guilliermondii é um dos componentes da microbiota
humana e infecções associadas com esta levedura têm sido incomuns,
o que pode ser atribuído a sua baixa patogenicidade. O objetivo deste
trabalho foi documentar aspectos clínico-epidemiológicos em pacientes
que tiveram C. guilliermondii isolada a partir de amostras biológicas.
O estudo foi conduzido na Santa Casa Complexo Hospitalar, Brasil.
Durante outubro de 1997 e outubro de 2003, C. guilliermondii foi
isolada de 11 pacientes, três dos quais foram excluídos por se
apresentarem apenas colonizados. Espécimes clínicos corresponderam
a sangue (n = 5), líquido de ascite (n = 2) e biópsia de esôfago (n = 1).
Três pacientes eram imunodeprimidos, incluindo transplante de órgãos
sólidos, SIDA e leucemia. Uso prévio de antimicrobianos ocorreu em
87,5% dos casos. Procedimentos médicos invasivos incluíram o uso
de cateteres venosos centrais (50,0%), cirurgia abdominal (25,0%) e
diálise peritonial (50,0%). Testes de susceptibilidade não foram
realizados. Embora fatores de risco para candidemia tenham sido
semelhantes entre pacientes infectados por C. guilliermondii ou outras
espécies de Candida, a mortalidade associada com C. guilliermondii
foi significativamente menor.
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